Early detection of Alzheimer’s disease (AD) can improve treatment outcomes, but current testing methods still have limitations. Researchers have long relied on cerebrospinal fluid (CSF) biomarkers and ...

Detecting toxic forms of tau before they weave into dense thickets of tangles could pave the way for earlier diagnosis and treatment of tauopathies, including Alzheimer’s disease. In the February 10 ...

For much of the past century, Alzheimer's disease has been one of medicine's most daunting frontiers—biologically complex, ...

Alzheimer's pathology was common in other dementias. An Alzheimer's biomarker profile was seen in unspecified dementia, Parkinson's dementia, and frontotemporal dementia. Biomarkers indicating ...

New test elevates the performance standard for blood biomarker tests intended for detecting amyloid pathology in individuals with cognitive impairment BILLERICA, Mass.--(BUSINESS WIRE)--Lucent ...

Global prevalence estimates show Alzheimer’s disease accounts for most dementia, with ~57 million people affected in 2021 and numbers projected to triple by 2050. People and health systems face rising ...

Brain-derived extracellular vesicle (EV) biomarkers represent a promising frontier for liquid biopsy development targeting the nervous system. They offer strong potential for enabling minimally ...

TORONTO — An expert panel convened by the Alzheimer’s Association has released the first clinical guidelines to help clinicians choose the most appropriate blood-based biomarker (BBM) test to aid in ...